NovaBay Pharmaceuticals - NBY Stock Forecast, Price & News

NovaBay Pharmaceuticals' stock was trading at $10.5945 on January 1st, 2022. Since then, NBY shares have decreased by 80.5% and is now trading at $2.0650.
View the best growth stocks for 2022 here.

NovaBay Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 37,300 shares, a decline of 96.6% from the October 31st total of 1,100,000 shares. Based on an average daily trading volume, of 55,400 shares, the days-to-cover ratio is presently 0.7 days.
View NovaBay Pharmaceuticals' Short Interest.

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) posted its earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts' consensus estimates of ($1.40) by $0.35. The biopharmaceutical company had revenue of $1.84 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 96.77% and a negative trailing twelve-month return on equity of 67.65%.

NovaBay Pharmaceuticals's stock reverse split before market open on Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT).

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

NovaBay Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Altium Capital Management LP (1.69%). Insiders that own company stock include Andrew D Jones, Audrey Kunin, Jeffrey Kunin, Jian Ping Fu, Justin Hall and Mijia Wu.
View institutional ownership trends.

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NBY stock can currently be purchased for approximately $2.07.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) has a market capitalization of $3.84 million and generates $9.93 million in revenue each year. The biopharmaceutical company earns $-11,030,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The official website for the company is novabay.com. The biopharmaceutical company can be reached via phone at (510) 899-8800, via email at jcain@lhai.com, or via fax at 510-474-1577.